SCIENTIFIC BACKGROUND

APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11

Category:

Scientific Background

Colorectal cancer is a genetic disease in which the cells in the colon or rectum divide uncontrollably forming tumors. In 2020, colorectal cancer was the 3rd most common type of cancer worldwide. Hereditary colorectal cancer accounts for about 5-10% of all colorectal cancer cases (Ferley et al., 2020). Patients with an inherited germline mutation have increased risk of developing colorectal cancer in the future. The genes tested in this panel have been identified to increase the risk of developing cancer in the future.

 

PreSENTIA hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

 

Who is this test for?

You should get tested if you meet at least one of the criteria below:

You have a personal history of colorectal cancer

You have a personal or family history of colorectal polyps

You have a personal or family history of other types of cancer

You have been diagnosed with colorectal cancer at a young age (<50)

You have first-degree relatives who have been diagnosed with colorectal cancer at a young age (<50)

You have been diagnosed with multiple primary cancers

 

How many genes are tested in this panel?

10 genes

 

How many hereditary cancer syndromes are associated with this panel?

6 Hereditary cancer syndromes are associated with this panel. These are:

Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)

• Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)

Juvenile Polyposis syndrome (SMAD4, BMPR1A)

• Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

• MUTYH-associated polyposis syndrome (MUTYH)

• Peutz-Jeghers syndrome (STK11)

 

Recommendations by professional bodies

The National Comprehensive Cancer Network (NCCN) recommends germline multigene panel testing for all individuals <50 years old who are diagnosed with colorectal cancer. Individuals who have a family history of colorectal cancer should also be considered for testing.  (NCCN, 2022)

 

References and more information: 

All the above information was taken from the National Cancer Institute, WHO, Colon Cancer Foundation

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer; 2020

GENES

APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11
How to order

LATEST ARTICLES

February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th...

Read more

Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor...

Read more

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more

Colorectal cancer remains a significant health concern globally. While genetic factors play a crucial role in its development, identifying the exact ...

Read more

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more